Bioventix PLC (AIM:BVXP)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 88.82M -36.4% |
| Revenue (ttm) | 12.54M -8.2% |
| Net Income | 7.44M -5.2% |
| EPS | 1.41 -5.1% |
| Shares Out | 5.22M |
| PE Ratio | 12.10 |
| Forward PE | n/a |
| Dividend | 1.50 (0.09%) |
| Ex-Dividend Date | Apr 9, 2026 |
| Volume | 1,557 |
| Average Volume | 8,726 |
| Open | 1,700.00 |
| Previous Close | 1,700.00 |
| Day's Range | 1,655.00 - 1,700.00 |
| 52-Week Range | 1,300.00 - 3,020.00 |
| Beta | n/a |
| RSI | 51.03 |
| Earnings Date | Jun 26, 2026 |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom. [Read more]
Financial Performance
In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.
Financial StatementsNews
AIM Market Roundup: Angle, Coyngar, Light Science Technologies
Angle, Coyngar, Light Science Technologies are today's top risers, while BioVentix, Great Western Mining take the biggest fall on AIM